References
1. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of
chromosomal abnormalities in childhood B-cell precursor acute
lymphoblastic leukaemia: results from the UK Medical Research Council
ALL97/99 randomised trial. Lancet Oncol . 2010;11(5):429-438.
doi:10.1016/S1470-2045(10)70066-8
2. Khabirova E, Jardine L, Coorens THH, et al. Single-cell
transcriptomics reveals a distinct developmental state of
KMT2A-rearranged infant B-cell acute lymphoblastic leukemia. Nat
Med . 2022;28(4):743-751. doi:10.1038/s41591-022-01720-7
3. Chen C, Yu W, Alikarami F, et al. Single-cell multiomics reveals
increased plasticity, resistant populations, and stem-cell-like blasts
in KMT2A-rearranged leukemia. Blood . 2022;139(14):2198-2211.
doi:10.1182/blood.2021013442
4. Tirtakusuma R, Szoltysek K, Milne P, et al. Epigenetic regulator
genes direct lineage switching in MLL/AF4 leukemia. Blood .
2022;140(17):1875-1890. doi:10.1182/blood.2021015036
5. Meyer C, Larghero P, Almeida Lopes B, et al. The KMT2A recombinome of
acute leukemias in 2023. Leukemia . Published online April 5,
2023. doi:10.1038/s41375-023-01877-1
6. Rossi JG, Bernasconi AR, Alonso CN, et al. Lineage switch in
childhood acute leukemia: an unusual event with poor outcome. Am J
Hematol . 2012;87(9):890-897. doi:10.1002/ajh.23266
7. Semchenkova A, Mikhailova E, Komkov A, et al. Lineage Conversion in
Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.Int J Mol Sci . 2022;23(7):4019. doi:10.3390/ijms23074019
8. Rayes A, McMasters RL, O’Brien MM. Lineage Switch in MLL-Rearranged
Infant Leukemia Following CD19-Directed Therapy. Pediatr Blood
Cancer . 2016;63(6):1113-1115. doi:10.1002/pbc.25953
9. Du J, Chisholm KM, Tsuchiya K, et al. Lineage Switch in an Infant
B-Lymphoblastic Leukemia With t(1;11)(p32;q23); KMT2A/EPS15, Following
Blinatumomab Therapy. Pediatr Dev Pathol . 2021;24(4):378-382.
doi:10.1177/10935266211001308
10. Pieters R, De Lorenzo P, Ancliffe P, et al. Outcome of Infants
Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the
Interfant-06 Protocol: Results From an International Phase III
Randomized Study. J Clin Oncol . 2019;37(25):2246-2256.
doi:10.1200/JCO.19.00261
11. Pullarkat VA, Lacayo NJ, Jabbour E, et al. Venetoclax and Navitoclax
in Combination with Chemotherapy in Patients with Relapsed or Refractory
Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer
Discov . 2021;11(6):1440-1453. doi:10.1158/2159-8290.CD-20-1465
12. Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination
with cytarabine with or without idarubicin in children with relapsed or
refractory acute myeloid leukaemia: a phase 1, dose-escalation study.Lancet Oncol . 2020;21(4):551-560.
doi:10.1016/S1470-2045(20)30060-7
13. Brethon B, Lainey E, Caye-Eude A, et al. Case Report: Targeting 2
Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia:
Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With
a KMT2A-Rearranged Leukemia. Front Oncol . 2021;11:637951.
doi:10.3389/fonc.2021.637951
14. Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis and cell
of origin of mixed phenotype acute leukaemia. Nature .
2018;562(7727):373-379. doi:10.1038/s41586-018-0436-0
15. Peham M, Panzer S, Fasching K, et al. Low frequency of clonotypic Ig
and T-cell receptor gene rearrangements in t(4;11) infant acute
lymphoblastic leukaemia and its implication for the detection of minimal
residual disease. Br J Haematol . 2002;117(2):315-321.
doi:10.1046/j.1365-2141.2002.03428.x
16. Van der Velden VHJ, Corral L, Valsecchi MG, et al. Prognostic
significance of minimal residual disease in infants with acute
lymphoblastic leukemia treated within the Interfant-99 protocol.Leukemia . 2009;23(6):1073-1079. doi:10.1038/leu.2009.17
17. Winters AC, Bernt KM. MLL-Rearranged Leukemias-An Update on Science
and Clinical Approaches. Front Pediatr . 2017;5:4.
doi:10.3389/fped.2017.00004
18. Ovilla-Martinez R, Weber Sánchez LA, Cota-Rangel X, Baez-Islas PE.
Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory
mixed-phenotype blast crisis in chronic myeloid leukaemia. BMJ
Case Rep . 2021;14(11):e243745. doi:10.1136/bcr-2021-243745
19. Stutterheim J, van der Sluis IM, de Lorenzo P, et al. Clinical
Implications of Minimal Residual Disease Detection in Infants With
KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the
Interfant-06 Protocol. J Clin Oncol . 2021;39(6):652-662.
doi:10.1200/JCO.20.02333
20. van der Sluis IM, de Lorenzo P, Kotecha RS, et al. Blinatumomab
Added to Chemotherapy in Infant Lymphoblastic Leukemia. N Engl J
Med . 2023;388(17):1572-1581. doi:10.1056/NEJMoa2214171